Taken toghether, this suggests that Rapalink-1, by inhibiting the activation of NF-κB (Figure 2), MAPKs (Figure 3), and mTOR (Figure 4), can suppress senescence (Figure 1) and can thus be beneficial against cardiovascular diseases [6]. Here, NFKB1 is linked to cardiovascular disorder.